It may go down 30-40% but will not close down to 40%. Novogen is now cashed up with two great potentials drugs on table that could make a hisotry if succcessful. Nasdaq act lot differently than ASX where global cashed up investors looking for a junior bio like Novogen that can bring great return in medium-long term. This will be soaked up at such a great discounted price.
Cheer
J
